Shares of Enzo Biochem have been flying over the past year due to increased demand for its clinical products, successful patent resolutions and new product introductions, says the company's president Barry Weiner. Enzo recently pocketed a multi-million dollar settlement from Affymetrix and Weiner expects the successful legal resolutions to continue without disrupting the ongoing business. Weiner also says the harsh winter weather hurt Enzo's clinical business in the first quarter as fewer patients braved the cold to go to the doctor, yet he expects that to normalize going forward.

More from Video

Video: What to Expect From Alphabet, Amazon and Facebook's Earnings This Week

Video: What to Expect From Alphabet, Amazon and Facebook's Earnings This Week

Should You Fear Earnings From Mega-Cap Tech Names Like Google and Microsoft?

Should You Fear Earnings From Mega-Cap Tech Names Like Google and Microsoft?

Wait, Google Was Almost Called What?

Wait, Google Was Almost Called What?

Alphabet Earnings and 4 Other Business Stories You Must Know Monday Morning

Alphabet Earnings and 4 Other Business Stories You Must Know Monday Morning

TheStreet Rewind: How to Make 'New Fashioned Wall Streeter'; Twist on a Classic

TheStreet Rewind: How to Make 'New Fashioned Wall Streeter'; Twist on a Classic